PTC Therapeutics Q3 revenue $217M (+57% YoY); raises DMD full-year guidance; secures $350M Blackstone financing

PTC THERAPEUTICS, INC.

2022-Q3 EPS reported -$5.43 revenue$531,389,000

Q3 total revenue $217.1M (+57% YoY); net product revenue $134.2M, royalty and collaboration $82.9M.
DMD franchise net product rev $131.4M (Translarna $76.6M, Emflaza $54.8M); full-year DMD guidance raised to $490-500M.
Strategic financing from Blackstone: initial $350M at close, option for additional $650M low-cost, low-dilution capital.
Net loss improved to $109.3M from $133.6M in Q3 2021; cash $288.4M as of Sep 30, 2022.
Clinical: EMA submission for Translarna standard approval; FDA meeting for Translarna US NDA; Upstaza BLA expected H1 2023.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

PTC THERAPEUTICS, INC. reported the quarter ended September 30, 2022 results: revenue $217.1 million, net income $(109.3) million. Guidance raised.

Period: the quarter ended September 30, 2022
Revenue: $217.1 million
Net income: $(109.3) million
Guidance: raised
Result: reported results

Exact text from the filing

into this Item 2.02. --- EX-99.1 (EX-99.1) --- PTC Therapeutics Provides a Corporate Update and Reports Third Quarter Financial Results - Total quarterly revenue of $217 million, representing 57% year-over-year growth – - 2022 DMD revenue guidance and low end of total revenue guidance increased - - Strategic financing with Blackstone with up to $1

View on SEC.gov

Browse all earnings releases →

PTC THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001070081-22-000038

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.